Third Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INC

Explicit Guidance:

• Cash Runway: Current cash, cash equivalents, and marketable securities ($431 million) are expected to fund operations through Q3 2028.
• License Milestone: An incremental $12 million milestone payment from GSK is expected in Q4 2026 following the selection of an siRNA development candidate.
• Revenue Outlook: No specific forward-looking revenue figures provided; revenue remains dependent on ongoing collaboration milestones with GSK.
• Share Count/Dividends: No guidance provided; company is currently in loss-making phase with no dividend or buyback programs.

Business-Segment Outlook:

• WVE-007 (Obesity):
  • Phase 2A Monotherapy: Enrollment underway for a global trial (BMI 35–50, comorbidities); expects data supporting the one-year regulatory threshold of >5% weight loss (based on body composition).
  • Phase 2A Combination: Trial evaluating WVE-007 + trisepatide (weekly) initiated in Q3 2026 for patients with BMI 35–50 and T2D; aims to demonstrate additive fat loss and muscle preservation.
  • Maintenance Strategy: Trial investigating WVE-007 as post-incretin maintenance to prevent weight regain planned for initiation in Q4 2026; aims to mitigate the ~70% weight regain observed after GLP-1 discontinuation.
  • Clinical Data: 600 mg single-ascending dose data expected in Q4 2026 to characterize potency and duration; 3-month interim data for Phase 2A may be released later in 2026 (subject to analysis).
• WVE-006 (AATD):
  • Registrational Trial: Planning underway for a single two-year pivotal trial with a one-year interim analysis for potential accelerated approval; design eliminates need for a separate confirmatory trial.
  • Dosing & Data: 600 mg monthly cohort data expected in Q4 2026 to inform optimal dose and regimen; aims to restore MZ-like phenotype and acute phase response.
• WVE-008 (PNPLA3 Liver Disease):
  • Timeline: First-in-human study to leverage genotyped populations; Clinical Trial Application (CTA) submission planned for 2026.
• GSK Collaboration: GSK has transitioned one development candidate to its pipeline; GSK retains rights to advance three additional programs towards development candidates.
• Platform: Continued validation of proprietary SPINA siRNA and RNA editing chemistry; focus on expanding hepatic/extrahepatic siRNA and bifunctional modalities.

Market and Competitive Outlook:

• Obesity Landscape: Positioning WVE-007 as a differentiated alternative to GLP-1s (incretins) by addressing muscle preservation (incretins cause ~40% muscle loss) and weight regain post-cessation (up to 70% regain of fat).
• Combination Potential: Anticipates potential for GLP-1 down-titration and enhanced efficacy in non-responders (up to 40% of patients fail GLP-1 goals); preclinical data suggests ~2x greater weight loss as an add-on.
• AATD Landscape: RNA editing (WVE-006) positioned as superior to IV plasma augmentation (no liver impact, static dosing) and DNA editing (safety concerns, high cost, irreversibility).
• Regulatory Trends: Engaging with FDA on moving beyond simple "weight loss" metrics to "body composition" (visceral fat reduction, lean mass preservation) as key efficacy drivers.

Macro / Industry Outlook:

• Regulatory Environment: FDA expressed high support for single-trial designs for accelerated and full approval in rare diseases (AATD), with potential for harmonization across CBER and CDER.
• Technology Recognition: Nobel Prize in Chemistry (chirality/stereochemistry) viewed as validation of the industry's focus on precise chemical design for efficacy and safety.
• Payer Challenges: RNA editing positioned as a sustainable first-line therapy compared to costly one-time DNA editing; emphasis on convenient subcutaneous dosing vs. frequent IV.
• Disease Awareness: Growing advocacy and clinical recognition of the limitations of BMI and scale weight; shift toward measuring visceral fat and body composition for regulatory and clinical decisions.

Strategic Initiatives:

• Talent Acquisition: Monica Vinuk joined as Chief Business Officer in Q3 2026 to expand platform partnerships and corporate development.
• Clinical Expansion: Advancing WVE-007 across three distinct settings (monotherapy, combination, maintenance) to define the treatment landscape for obesity.
• Research Day: Upcoming event to detail capabilities in hepatic/extrahepatic siRNA, RNA editing, and bifunctional modalities.
• Partnership Strategy: Active ongoing discussions to capitalize on clinical and preclinical portfolios and the proprietary platform.
• Capacity/Clinical Sites: Leveraging patient registries and foundations (Alpha-1 community) to accelerate enrollment for AATD trials globally.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: While FDA alignment was positive for AATD, specific biomarker thresholds for full approval (functional outcomes vs. biomarkers) remain subject to final negotiation.
• Clinical Execution: Trial enrollment speed depends on community engagement; potential for delays in data analysis or dose selection for maintenance studies.
• Competitive Pressure: Rapid evolution of incretin landscape and other siRNA/RNA editing programs (e.g., Arrowhead, Takeda) requires differentiation on body composition and dosing convenience.
• Safety: Potential for dose-dependent safety issues (liver enzymes) as doses escalate or as novel modalities (bifunctional) are introduced.
• Financials: Dependence on GSK milestone payments and potential future collaborations to extend cash runway beyond Q3 2028.
• Caveats: "Actual results may differ materially" due to risks in development, manufacturing, and regulatory approval; no obligation to update forward-looking statements.

Management Tone on the Future:

• Confidence: High confidence in the ability to cross the 5% weight loss regulatory threshold with WVE-007 due to high baseline adiposity in Phase 2A.
• Optimism: Strong belief that WVE-007 can "redefine the treatment landscape" in obesity through muscle preservation and long-term durability (once/twice yearly).
• Efficiency: Pride in the streamlined, single-trial design for WVE-006 that offers a path to full approval without a separate confirmatory study.
• Strategic Alignment: View of the GSK partnership as mutually beneficial and evolving positively despite past leadership changes; confident in platform value as evidenced by GSK's recent selection.
• Tone Summary: Aggressive but measured; focused on "expeditiously" advancing programs to unlock value while navigating complex regulatory and competitive landscapes.

Miscellaneous:

• Dosing Frequency: Goal for WVE-007 is once or twice yearly dosing; WVE-006 currently targeted for monthly dosing, with 600 mg data expected to inform if less frequent (bi-weekly or less) is feasible.
• Assay Validation: FDA comfort level expressed regarding the use of specific LC-MS assays for measuring M and Z proteins in AATD studies, ensuring consistency from Phase 1 through registration.
• Enrichment Strategy: Phase 2A obesity trial specifically targets higher BMI/comorbid patients to maximize fat loss signal and de-risk MASH development pathways.